Healthcare provider profile · identity verified

Gregory K Gahl, MD

Allopathic & Osteopathic Physicians|Family Medicine · MUNCIE, IN · NPI 1124105879

Profile state: payments and partd Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

CMS Open Payments records show Gregory K Gahl, MD received $101.26 in general payments during 2025 across 5 reported records.

Abbott Laboratories accounted for 35.4% of that reported general-payment amount.

The Open Payments records used for this analysis explicitly named 3 associated products.

A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.

Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Jardiance by this doctor in 2024.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

$101.26

5 reported records · 4 companies

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Who paid this doctor?

Companies in 2025 General Payments

Reported company	Canonical company	Amount	Share	Records	Year
Abbott Laboratories	Unresolved — no canonical attribution shown	$35.88	35.4%	2	2025
Dexcom, Inc.	Unresolved — no canonical attribution shown	$27.27	26.9%	1	2025
RGH Enterprises LLC	Unresolved — no canonical attribution shown	$19.26	19.0%	1	2025
Boehringer Ingelheim Pharmaceuticals, Inc.	Unresolved — no canonical attribution shown	$18.85	18.6%	1	2025

What were the payments for?

Payment categories

Category	Amount	Records
Food and Beverage	$82.41	4
Education	$18.85	1

A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.

Analysis 1 · Payment-linked products

Products named in Open Payments records

Reported product	Type	Reported company	Related amount*	Records	Year
FREESTYLE LIBRE 3 Normalized: freestyle libre 3	Device	Abbott Laboratories	$35.88	2	2025
Source payment records 2025-01-02 · Abbott Laboratories · $14.99 · Open Payments source 2025-05-23 · Abbott Laboratories · $20.89 · Open Payments source
Dexcom G6 Transmitter Normalized: dexcom g6 transmitter	Medical Supply	Dexcom, Inc.	$27.27	1	2025
Source payment records 2025-07-10 · Dexcom, Inc. · $27.27 · Open Payments source
JARDIANCE Normalized: jardiance	Drug	Boehringer Ingelheim Pharmaceuticals, Inc.	$18.85	1	2025
Source payment records 2025-02-19 · Boehringer Ingelheim Pharmaceuticals, Inc. · $18.85 · Open Payments source

* Product-associated amounts are non-additive because one payment record may name more than one product.

These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.

Public prescribing for products named in payments

Open Payments product	Payment year	Part D brand	Part D year	Claims	Match method	Source
JARDIANCE jardiance	2025	Jardiance	2024	68	exact normalized	Medicare Part D

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

Paying company	Payment year	Drug reported by same entity	Open Payments evidence	Part D	Claims	Beneficiaries
Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference	2025	JARDIANCE open payments reported associated product	CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583	Jardiance · 2024 Exact normalized brand match · 1 Part D row	68	17

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	595	177
Amlodipine Besylate	Amlodipine Besylate	416	123
Levothyroxine Sodium	Levothyroxine Sodium	383	106
Lisinopril	Lisinopril	278	82
Pantoprazole Sodium	Pantoprazole Sodium	257	79
Losartan Potassium	Losartan Potassium	241	75
Omeprazole	Omeprazole	215	65
Hydrochlorothiazide	Hydrochlorothiazide	198	63
Metformin Hcl	Metformin Hcl	195	59
Rosuvastatin Calcium	Rosuvastatin Calcium	193	56
Metformin Hcl Er	Metformin Hcl	192	56
Tamsulosin Hcl	Tamsulosin Hcl	187	59
Pravastatin Sodium	Pravastatin Sodium	180	54
Albuterol Sulfate Hfa	Albuterol Sulfate	175	56
Carvedilol	Carvedilol	167	53
Metoprolol Succinate	Metoprolol Succinate	162	53
Gabapentin	Gabapentin	140	40
Famotidine	Famotidine	99	35
Montelukast Sodium	Montelukast Sodium	99	32
Meloxicam	Meloxicam	95	27
Allopurinol	Allopurinol	94	28
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	93	26
Sertraline Hcl	Sertraline Hcl	87	24
Furosemide	Furosemide	85	35
Potassium Chloride	Potassium Chloride	82	24
Simvastatin	Simvastatin	82	29
Mounjaro	Tirzepatide	78	17
Metoprolol Tartrate	Metoprolol Tartrate	70	22
Jardiance	Empagliflozin	68	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	67	26
Escitalopram Oxalate	Escitalopram Oxalate	66	21
Buspirone Hcl	Buspirone Hcl	64	18
Glipizide Er	Glipizide	63	16
Shingrix	Varicella-Zoster Ge/As01b/Pf	62	56
Alendronate Sodium	Alendronate Sodium	61	20
Fluticasone Propionate	Fluticasone Propionate	61	30
Pioglitazone Hcl	Pioglitazone Hcl	61	20
Eliquis	Apixaban	59	14
Trelegy Ellipta	Fluticasone/Umeclidin/Vilanter	58	11
Spironolactone	Spironolactone	57	17
Zolpidem Tartrate	Zolpidem Tartrate	56	suppressed
Ezetimibe	Ezetimibe	55	17
Doxycycline Hyclate	Doxycycline Hyclate	54	49
Trulicity	Dulaglutide	50	suppressed
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	14
Valsartan	Valsartan	49	11
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	47	12
Trazodone Hcl	Trazodone Hcl	44	16
Atenolol	Atenolol	43	16
Dicyclomine Hcl	Dicyclomine Hcl	43	suppressed
Hydroxyzine Hcl	Hydroxyzine Hcl	43	16
Ropinirole Hcl	Ropinirole Hcl	43	13
Synthroid	Levothyroxine Sodium	40	suppressed
Alprazolam	Alprazolam	39	11
Venlafaxine Hcl Er	Venlafaxine Hcl	39	suppressed
Glipizide	Glipizide	38	suppressed
Prednisone	Prednisone	38	34
Benazepril Hcl	Benazepril Hcl	36	11
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	36	11
Bupropion Xl	Bupropion Hcl	35	11
Januvia	Sitagliptin Phosphate	35	12
Duloxetine Hcl	Duloxetine Hcl	34	suppressed
Fluticasone-Salmeterol	Fluticasone Propion/Salmeterol	34	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	33	12
Telmisartan	Telmisartan	33	suppressed
Clopidogrel	Clopidogrel Bisulfate	32	suppressed
Ramipril	Ramipril	32	suppressed
Clonidine Hcl	Clonidine Hcl	31	11
Fluoxetine Hcl	Fluoxetine Hcl	29	suppressed
Ozempic	Semaglutide	29	suppressed
Breo Ellipta	Fluticasone/Vilanterol	28	suppressed
Citalopram Hbr	Citalopram Hydrobromide	28	11
Azithromycin	Azithromycin	27	26
Cephalexin	Cephalexin	27	22
Nifedipine Er	Nifedipine	27	suppressed
Raloxifene Hcl	Raloxifene Hcl	27	suppressed
Torsemide	Torsemide	27	suppressed
Xarelto	Rivaroxaban	27	suppressed
Tramadol Hcl	Tramadol Hcl	26	suppressed
Glimepiride	Glimepiride	25	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Celecoxib	Celecoxib	24	suppressed
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	24	suppressed
Mupirocin	Mupirocin	24	22
Propranolol Hcl	Propranolol Hcl	24	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Pregabalin	Pregabalin	23	suppressed
Budesonide-Formoterol Fumarate	Budesonide/Formoterol Fumarate	22	suppressed
Pramipexole Dihydrochloride	Pramipexole Di-Hcl	22	suppressed
Symbicort	Budesonide/Formoterol Fumarate	22	suppressed
Janumet Xr	Sitagliptin Phos/Metformin Hcl	21	suppressed
Meclizine Hcl	Meclizine Hcl	21	13
Sucralfate	Sucralfate	21	suppressed
Chlorthalidone	Chlorthalidone	20	suppressed
Hydralazine Hcl	Hydralazine Hcl	20	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	19	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	19	suppressed
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	19	suppressed
Paroxetine Hcl	Paroxetine Hcl	19	suppressed
Spiriva Respimat	Tiotropium Bromide	19	suppressed
Humulin 70-30	Insulin Nph Hum/Reg Insulin Hm	18	suppressed
Incruse Ellipta	Umeclidinium Bromide	18	suppressed
Memantine Hcl	Memantine Hcl	18	suppressed
Nitrofurantoin Mono-Macro	Nitrofurantoin Monohyd/M-Cryst	18	16
Nortriptyline Hcl	Nortriptyline Hcl	18	suppressed
Solifenacin Succinate	Solifenacin Succinate	18	suppressed
Tizanidine Hcl	Tizanidine Hcl	18	suppressed
Colchicine	Colchicine	17	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	17	suppressed
Finasteride	Finasteride	17	suppressed
Irbesartan	Irbesartan	17	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	17	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	17	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	17	suppressed
Amoxicillin	Amoxicillin	16	15
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	16	13
Nystatin	Nystatin	16	11
Ondansetron Hcl	Ondansetron Hcl	16	suppressed
Tresiba Flextouch U-200	Insulin Degludec	16	suppressed
Estradiol	Estradiol	15	suppressed
Gemtesa	Vibegron	15	suppressed
Oxybutynin Chloride	Oxybutynin Chloride	15	suppressed
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	15	14
Triamcinolone Acetonide	Triamcinolone Acetonide	15	14
Verapamil Er	Verapamil Hcl	15	suppressed
Divalproex Sodium	Divalproex Sodium	14	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	14	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	14	suppressed
Naproxen	Naproxen	14	suppressed
Amlodipine-Valsartan	Amlodipine Besylate/Valsartan	13	suppressed
Betamethasone Valerate	Betamethasone Valerate	13	suppressed
Diclofenac Sodium	Diclofenac Sodium	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	13	suppressed
Pulmicort Flexhaler	Budesonide	13	suppressed
Advair Hfa	Fluticasone Propion/Salmeterol	12	suppressed
Breztri Aerosphere	Budesonide/Glycopyr/Formoterol	12	suppressed
Enalapril Maleate	Enalapril Maleate	12	suppressed
Fentanyl	Fentanyl	12	suppressed
Ketoconazole	Ketoconazole	12	suppressed
Topiramate	Topiramate	12	suppressed
Bupropion Hcl Sr	Bupropion Hcl	11	suppressed
Cholestyramine	Cholestyramine (With Sugar)	11	suppressed
Clonazepam	Clonazepam	11	suppressed
Combivent Respimat	Ipratropium/Albuterol Sulfate	11	suppressed
Insulin Lispro Kwikpen U-100	Insulin Lispro	11	suppressed
Oxybutynin Chloride Er	Oxybutynin Chloride	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	$101.26 · 5 records	Abbott Laboratories	Dexcom G6 Transmitter, FREESTYLE LIBRE 3, JARDIANCE	1	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

What role, if any, does Jardiance play in your treatment recommendations for me?
How do you evaluate evidence when you have a financial relationship with Boehringer Ingelheim Pharmaceuticals, Inc.?
Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error